Alexandria Real Estate Equities (ARE) Q3 2025 10-Q Quarterly Report
Alexandria Real Estate Equities (ARE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 27, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Alexandria Real Estate Equities Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue not explicitly stated; FFO $377.8M, down 7.4% YoY from $407.9M for Q3 2024
- • Net loss $234.9M vs net income $164.7M YoY for Q3; per share loss $(1.38) vs income $0.96
Risk Factors
- • Newly added risk: FDA laid off 3,500 employees (19% of workforce) in 2025 disrupting regulatory approvals and R&D timelines for tenants
- • Most materially updated risk: NIH budget freeze reversed but FY2026 proposal cuts NIH funding by 40% from $48B to $27.5B impacting research funding
Alexandria Real Estate Equities Q3 2025 Quarterly FinancialsXBRL
Revenue
$752M
▼ -5.0% YoY▼ -1.3% QoQ
Net Income
-$233M
▼ -238.6% YoY▼ -117.5% QoQ
Net Margin
-31.0%
▼ -5217bp YoY▼ -1691bp QoQ
ROE
-1.4%
Total Assets
$37.4B
EPS (Diluted)
$-1.38
▼ -243.8% YoY▼ -115.6% QoQ
Operating Cash Flow
$433M
▼ -9.2% YoY▼ -5.8% QoQ
Source: XBRL data from Alexandria Real Estate Equities Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Alexandria Real Estate Equities Quarterly Reports
Get deeper insights on Alexandria Real Estate Equities
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.